0.475
전일 마감가:
$0.488
열려 있는:
$0.488
하루 거래량:
1.24M
Relative Volume:
0.41
시가총액:
$77.27M
수익:
-
순이익/손실:
$-111.13M
주가수익비율:
-0.3598
EPS:
-1.32
순현금흐름:
$-91.53M
1주 성능:
+20.74%
1개월 성능:
+5.82%
6개월 성능:
-78.55%
1년 성능:
-88.80%
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
TNYA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TNYA
Tenaya Therapeutics Inc
|
0.475 | 66.86M | 0 | -111.13M | -91.53M | -1.32 |
![]()
ONC
Beigene Ltd Adr
|
234.99 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.10 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
604.72 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.93 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-10 | 개시 | William Blair | Outperform |
2023-11-30 | 개시 | Leerink Partners | Outperform |
2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Price T Rowe Associates Inc. MD Sells 2,892,201 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya therapeutics SVP Higa Tomohiro sells $615 in stock By Investing.com - Investing.com India
Tenaya Therapeutics chief medical officer sells $1,300 in stock - Investing.com
Tenaya therapeutics SVP Higa Tomohiro sells $615 in stock - Investing.com
Tenaya Therapeutics Awards Major Stock Options Package: 461K Shares for Strategic New Hires - Stock Titan
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Greenlane Renewables Announces First Quarter 2025 Financial Results - The Globe and Mail
Barclays PLC Sells 184,837 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (TNYA) to Showcase Key Research at ASGCT 202 - GuruFocus
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting - The Manila Times
Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting - Nasdaq
Tenaya Therapeutics to Highlight Capsid Engineering, Gene - GlobeNewswire
Hsbc Holdings PLC Purchases New Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Yahoo Finance
Chardan Capital Maintains Buy Rating for Tenaya Therapeutics (TNYA) | TNYA Stock News - GuruFocus
Tenaya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Tenaya (TNYA) Reports Promising Clinical Trial Developments and Financial Outlook | TNYA Stock News - GuruFocus
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
A Cautious Investment in the Drone Sector - The Globe and Mail
Geode Capital Management LLC Sells 27,419 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock - Investing.com Australia
TNYATenaya Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Tenaya reports progress in ARVC gene therapy study - Investing.com
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 - The Manila Times
Tenaya Therapeutics Presents Interim Data from RIDGE™ - GlobeNewswire
Major Breakthrough: 175-Patient ARVC Study Shows 93% Could Benefit from New Gene Therapy Treatment - Stock Titan
Tenaya reports progress in ARVC gene therapy study By Investing.com - Investing.com UK
Strategy (MSTR) Buys Another $556 Million Worth of Bitcoin - The Globe and Mail
Tenaya Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com India
Tenaya Therapeutics faces Nasdaq delisting over share price - Investing.com Australia
Alignment Healthcare to Announce First Quarter 2025 Financial Results and Host Conference Call Thursday, May 1, 2025 - The Globe and Mail
Strategic Win: Kalaris Lands Former CEO and CFO Powerhouse for Board Leadership - Stock Titan
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Tenaya highlights HCM gene therapy interim data at ACC 2025 - Yahoo
Tenaya Slashes a Third of Workforce To Fund Development of Cardio Gene Therapies - BioSpace
Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
Tenaya Therapeutics Announces Late Breaker Presentation - GlobeNewswire
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan
Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus
Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN
FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):